ZOMDF
Zomedica Corp.0.1120
+0.0020+1.82%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
109.75MP/E (TTM)
-Basic EPS (TTM)
-0.09Dividend Yield
0%Recent Filings
8-K
Q3 revenue hits $8.1M
Zomedica reported Q3 2025 revenue of $8.1 million, up 16% from Q3 2024, with diagnostics surging 51% to $0.7 million and new Development Services adding $0.7 million. Gross margins hit 67%, OPEX fell $0.5 million, and net loss narrowed 9% to $6.1 million. $54.4 million liquidity fuels growth. Record quarter. Risks linger on Development Services continuity.
10-Q
Q3 FY2025 results
Zomedica posted Q3 revenue of $8.1M, up 16% y/y from $7.0M, with Therapeutic Devices at $6.7M (83% of total) and new Development Services adding $0.7M; gross margin slipped to 67% from 72% on higher depreciation (derived). YTD revenue climbed 11% y/y to $21.6M, but $55.8M impairment hit—$45.6M goodwill, $8.3M intangibles, $2.0M property—drove operating loss to $79.2M from $42.9M, with net loss widening to $(0.08) per share versus $(0.04). Cash burn eased to $16.8M operating outflow; $7.5M cash plus $46.9M available-for-sale securities back $56M working capital. No debt. Impairments stemmed from market cap drop post-NYSE delisting.
8-K
Q2 revenue hits $7M
Zomedica reported Q2 revenue up 14% to $7.0 million, marking its 18th straight record quarter, fueled by 86% diagnostics growth to $0.8 million and 21% consumable sales rise to $5.3 million. Gross margins held at 67%, OPEX fell $0.7 million via cuts, narrowing net loss to $7.4 million. Liquidity stands firm at $59.1 million. Cost controls sharpen profitability path.
10-Q
Q2 FY2025 results
Zomedica posted Q2 revenue of $7.0M, up 14% y/y from $6.1M yet flat q/q, with Therapeutic Devices at $6.2M (89% of total) driving consumables growth while Diagnostics lagged at $0.8M; gross margin held at 67%, down from 71% y/y on higher depreciation (derived). Losses narrowed sharply to $8.0M operating and $7.4M net from $25.1M/$23.9M y/y, absent Q1's $55.8M impairments on goodwill ($45.6M), intangibles ($8.3M), and property ($2.0M) tied to post-delisting market drop. Cash burn eased to $12.1M operating (capex $0.6M, no FCF), ending with $8.1M cash plus $50.9M short-term securities and zero debt. Impairments cleared the balance sheet. Steady revenue builds momentum.
8-K
Shareholders reject exec pay
Zomedica shareholders at the June 10, 2025 annual meeting elected all eight director nominees and ratified Grant Thornton as auditors for 2025. Executive compensation failed advisory approval, with 82M against versus 57M for amid 208M broker non-votes. Investors signal pay concerns. Governance stays intact.
BDMD
Baird Medical Investment Holdin
1.37+0.02
BMRA
Biomerica, Inc.
2.37-0.08
CNMD
CONMED Corporation
39.20-1.12
MDNC
MEDINOTEC INC
5.00+0.00
PETV
PetVivo Holdings Inc.
1.16-0.03
PROF
Profound Medical Corp.
7.55-0.14
QDEL
QuidelOrtho Corporation
28.88-0.18
RBOT
Vicarious Surgical Inc.
2.43-0.04
ZIMV
ZimVie Inc.
18.99+0.00
ZTS
Zoetis Inc.
123.23+2.25